Anti-Human/Rat HER2 (neu) Antibody (7.16.4)
Based on 1 Customer Validation
Anti-Human/Rat HER2 (neu) Antibody (7.16.4) is an anti-human and anti-rat HER2 IgG2a monoclonal antibody. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) reduces tumor cell proliferation by inhibiting the HER2 signaling pathway. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) can activate CD8+ T cells. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) can be used for research on cancer such as breast cancer.
For research use only. We do not sell to patients.
- Purity : 95.00%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All EGFR Isoforms
More
Biological Activity
Description
Isotype
Mouse IgG2a kappa
Recommend Isotype Controls
Species Reactivity
Human/Rat
IC50 & Target
HER2 (neu)
In Vitro
The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Anti-Human/Rat HER2 (neu) Antibody (7.16.4) (100 μg, i.p., once daily, from day 13 to day 17) delays tumor growth in female BALB/c mice bearing TUBO tumors[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:5×105 TUBO cells injected female BALB/c mice (5 weeks)[1]
-
Dosage:10 mg/kg, combined with Pyrotinib (10 mg/kg, p.o., 5 times a week)
-
Administration:Intraperitoneal injection (i.p.), twice a week, for 21 days
-
Result:Significantly inhibited tumor volume.
Significantly inhibited the HER2 signaling pathway (downregulation of pHER2, pAKT, pERK).
Reduced tumor cell proliferation.
Did not significantly affect the weight of mice.
-
Animal Model:8×105 TUBO cells injected female BALB/c mice (6-8 weeks)[2]
-
Dosage:100 μg
-
Administration:Intraperitoneal injection (i.p.), once daily from day 13 to day 17
-
Result:Delayed tumor growth, but could not completely eliminate the tumor.
Increased the proportion of PD-1+ CD8+ T cells.
Gene ID
Accession
AAH61863
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Application
in vivo HER2/neu inhibition; in vitro HER2/neu inhibition; Immunoprecipitation; Immunofluorescenc
Verified Bioactivity
-
Flow cytometric analysis of 1×106 MCF-7 cells labeling Anti-Human/Rat HER2 (neu) Antibody (7.16.4) (HY-P990238, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Mouse IgG2a kappa Isotype Control (HY-P99978, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Human/Rat HER2 (neu) Antibody (7.16.4)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Liu S, et al. Pyrotinib and trastuzumab combination treatment synergistically overcomes HER2 dependency in HER2-positive breast cancer: insights from the PHILA trial. EBioMedicine. 2024 Nov;109:105379. [Content Brief]
[2]. Xu M, Du X, Liu M, Li S, Li X, Fu YX, Wang S. The tumor immunosuppressive microenvironment impairs the therapy of anti-HER2/neu antibody. Protein Cell. 2012 Jun;3(6):441-9. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Human/Rat HER2 (neu) Antibody (7.16.4) Related Classifications
HY-P990238 Related Classifications
Powered by Bioz